Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21309558 | 0.78 | ACLY (0.48) | ACLYCA1CA2CA9F2 | |
| SCHEMBL11323103 | 0.75 | ACLY (0.42) | ACLYCA1CA2CA9 | |
| SCHEMBL21309701 | 0.74 | ACLY (0.40) | ACLY | |
| Hydrochloric Acid SCHEMBL11323108 | 0.74 | ACLY (0.52) | ACLYHIF1A | |
| SCHEMBL21309392 | 0.73 | ACLY (0.35) | ACLYCA1CA2 | |
| SCHEMBL21294319 | 0.71 | ACLY (0.34) | ACLYCA1CA2 | |
| SCHEMBL21309559 | 0.71 | CXCR5 (0.50) | ACLYCA1CA2CA9CASR | |
| SCHEMBL10981786 | 0.70 | CYP1A2 (0.45) | CYP1A2CYP2C9HIF1ACA1CA2 | |
| SCHEMBL24401752 | 0.69 | LMNA (0.46) | ACLYCA1CA2CA9LMNA | |
| SCHEMBL11513312 | 0.69 | CA1 (0.39) | ACLYCA1CA2CA9F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| CN-109922835-B | DCHBS active ester of PEG compound and application thereof | 诺和诺德股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-3534962-B1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | NOVO NORDISK AS (DK) | 2020-08-19 | — | — | EP | disclosed |
| EP-3534962-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | Novo Nordisk A/S (DK) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263854-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | NOVO NORDISK A/S (DK) | 2019-08-29 | — | — | US | disclosed |
| US-20190263854-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | NOVO NORDISK A/S (DK) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263854-A1 | DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE | HBB, IAPP, GLP1R | ACLY 181/4885CYP1A2 4727/4885CYP2C9 3987/4885 |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | HBB, IAPP, GLP1R | ACLY 181/4885CYP1A2 4727/4885CYP2C9 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.